Oncologists near North Bergen, NJ

Biography: Dr. Sathe completed her Residency in Internal Medicine at NYP/Weill Cornell and is a graduate of Rutgers-New Jersey Medical School. She also holds a JD from Columbia Law School. Her research focuses on improving cancer care delivery and reducing disparities in treatment and outcomes.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. Lentzsch is a Professor of Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Irving Medical Center/NewYork-Presbyterian Hospital. She received her medical and doctorate degrees from Humboldt University in Berlin, Germany, where she also completed her residency and fellowship. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr. Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA. Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia. Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.

Biography: James H. Garvin, MD, PhD, is a board-certified pediatric hematologist-oncologist who specializes in the care of children and adolescents with brain tumors. He is Principal Investigator at CUMC for the Head Start Program of radiation-sparing intensive chemotherapy for infants and young children with brain tumors. He was principal investigator for a Children's Oncolgy Group protocol for childhood ependymoma. He also offers novel therapies for recurrent brain tumors through our program's membership in Developmental Therapeutics Program of the COG. In addition, Dr. Garvin started the pediatric bone marrow transplant program, and continues as a member of the BMT group. He has particular interest in autologous transplant for brain tumors and allogeneic transplant for metabolic disorders and bone marrow failure syndromes, as well as supportive care for BMT patients. Dr. Garvin became interested in pediatric hematology/oncology through research during medical school in the laboratory of a pediatric hematologist. He is a member of numerous professional societies in the field.

Biography: Dr. Andrew H. Lipsky is an Assistant Professor of Medicine at the Columbia University Medical Center. He specializes in caring for adult patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL) and lymphoma.Dr. Lipsky's research focuses on cancer genomics and new treatments for CLL. He has a special interest in using the latest bioinformatics techniques to study how cancer cells change and adapt during treatment. Utilizing these genomic insights, he hopes to better inform clinical trials and hasten the development of innovative therapies for patients with hematologic malignancies.Dr. Lipsky earned his medical degree from Rutgers - Robert Wood Johnson Medical School. He completed internship and residency in internal medicine at Montefiore - Albert Einstein College of Medicine. He completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital Weill Cornell Medical College, with an additional sub-fellowship in the clinical care of CLL and lymphoma. He also completed a postdoctoral research fellowship in lymphoma genomics and bioinformatics as part of the Molecular and Translation Oncology Research (MTOR) training program.

Care Philosophy: I am a medical oncologist who specializes in cancers of the lung and thymus. I work closely with our multidisciplinary team of expert thoracic surgeons, radiation oncologists, interventional radiologists, palliative care/pain management specialists, and nutritionists to provide comprehensive care for our patients. I view each patient and their disease as unique and work to manage their treatment accordingly, always keeping their goals in mind. In order to provide new hopes for the future of lung cancer treatment, our division is also involved in clinical research focusing on precsion medicine, immunotherapy, and novel therapeutics as well as laboratory research to better understand this disease.

Biography: Dr. Konstantin Zakashansky, MD is an Oncology Specialist who practices in New York, NY. He is 54 years old and has been practicing for 25 years. Dr. Konstantin Zakashansky, MD is affiliated with Mount Sinai Morningside, Mount Sinai Queens and Mount Sinai Brooklyn.

Biography: Meghna S. Trivedi, MD, MS cares for patients diagnosed with breast cancer. Dr. Trivedi received her medical degree from the University of Maryland School of Medicine, and completed her residency at the University of Pennsylvania. She went on to complete her fellowship in hematology/oncology at Columbia University. Dr. Trivedi co-leads the Hereditary Breast and Ovarian Cancer Program, a comprehensive, multi-disciplinary initiative aimed at screening, preventing, diagnosing, and treating hereditary breast and ovarian cancer. This innovative program brings together the resources of a world-renowned academic institution, including cutting-edge genomic testing, clinical trials, and experts in hereditary cancers across different specialties. Dr. Trivedi's research and care expertise also includes cancer genetics and genomics, precision medicine, and chemotherapy induced peripheral neuropathy. She is the principal investigator on several clinical trials, and has authored numerous publications in leading peer-reviewed journals. Dr. Trivedi is a member of the American Society of Clinical Oncologists and SWOG.

Biography: Dr. Catherine Small, MD is an Oncology Specialist who practices in New York, NY. She has been practicing for 27 years. Dr. Catherine Small, MD is affiliated with Weill Cornell Medical Center.

Biography: Monica Bhatia, MD specializes in the care of children with noncancerous blood disorders who may benefit from bone marrow transplantation, especially sickle cell anemia. She and her colleagues are working to reduce the toxicity (side effects) and complications of this treatment without compromising its effectiveness, and to make it available to more patients. The field of pediatric hematology brings with it many intellectual challenges, and bone marrow transplantation in particular is especially dynamic. Dr. Bhatia has the opportunity to provide care for the sickest children, potentially curing their disease. She builds strong relationships with her patients and their families that last for years. It is inspiring for her to see young patients grow up to lead healthy, productive lives. NewYork-Presbyterian/Morgan Stanley Children's Hospital has a robust program for bone marrow transplantation for sickle cell anemia - the only cure for this disease. Dr. Bhatia and her team have witnessed remarkable results among children who are cured with bone marrow transplantation and spared from the potentially life-threatening complications of sickle cell disease. Yet despite the advances made, only 15 percent of patients with sickle cell disease have a matched sibling bone marrow donor. Therefore, Dr. Bhatia and her team conduct research to evaluate a procedure called "CD34-selected stem cell transplantation" to remove T-cells from donor bone marrow for patients without a matched sibling donor. This approach reduces the risk of graft-versus-host disease (GVHD), a potential complication of bone marrow transplantation in which T-cells from the donor attack the tissue of the recipient. This approach to harnessing stem cells could potentially make bone marrow transplantation a safer, effective option for many patients who are seeking a cure for sickle cell disease. Dr. Bhatia and her colleagues are currently assessing reduced-intensity transplantation, which uses lower doses of chemotherapy to decrease the risk of side effects and long-term complications without lowering the effectiveness of treatment. She is also interested in looking for ways to further improve the quality of life of patients who have had a bone marrow transplant in addition to fertility preservation.

Care Philosophy: For detailed information about Dr. Sekhri and Advanced Care Oncology and Hematology Associates (ACOHA) please visit www.njacoha. com. The practice was founded with a mission of providing the highest level of quality cancer and hematology care in a personalized, integrative approach. We care for adults with a wide range of blood disorders and cancers and treat patients by encompassing a 360 degree integrated approach in a private setting. Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

Care Philosophy: As a board-certified general surgeon and surgical oncologist, I firmly believe in providing the best care to all of my patients. I believe in spending time with patients and families to ensure that they understand all of the options available to them. When surgery is indicated and the best course of action, I provide patients with the best surgical and medical care to ensure they can return to their lives and families.

Care Philosophy: It is a privilege to take care of patients with breast cancer. Each patient is different, each breast cancer is different and treatment recommendations are tailored to the individual patient. At the Weill Cornell Breast Center, we work as a team to recommend the optimal treatment plan for each patient. We have begun a new initiative, a "survivorship" program to study and support our patients throughout their lifetime after a breast cancer diagnosis. It is exciting to be in the forefront of breast cancer research not only with our own group at the Breast Center but also as part of the exciting research going on across the nation. Every year brings advances in this field. I am very happy to be part of it!

Care Philosophy: Everything that we do at our center, whether clinical care, research or education, is focused on helping patients. Here are some of the many reasons why patients tell us they come here - whether from the New York area, the surrounding region, or traveling from all over the country and other parts of the world in order to receive evaluation and treatment for lymphoma by our group. Patients seek treatment here because they are referred here by their physicians, who recognize our expertise and know that across the region and the country we are a "go to" place to seek the best lymphoma care. Our physicians are internationally recognized for clinical skill, research, and personal qualities. In fact, we care for a substantial number of individual physicians (or their family members) who are themselves dealing with lymphoma.

Care Philosophy: I am a medical oncologist dedicated to treating and studying diseases that affect the genitourinary system. At Weill Cornell Medicine, I work at the intersection of science and patient care, which allows me to combine my medical training and research insights to provide the best possible care to adults with kidney, bladder, prostate and testicular cancers. It is a priority of mine to not only deliver cutting-edge and compassionate care to my patients, but to enhance the quality of life for patients and their families as they cope with a cancer diagnosis. I feel privileged to collaborate with a multidisciplinary, world-class team of clinicians, nurses, social workers and other cancer sub-specialists. Together, we are able to offer an extraordinary level of expertise and support to our patients at all stages of disease. Additionally, my scientific work involves translational research and clinical trials to investigate promising, new treatment therapies. This allows us to move the field forward in order to one day find cures for cancer.

Care Philosophy: As far back as I remember, I have been interested in improving the care of patients with cancer through research aimed at developing new and more effective therapies, and by providing compassionate care. I am fortunate to work at an institution that enables me to care for patients within an outstanding hospital and medical college, where I am surrounded by like-minded physicians and staff that are most concerned about the well-being of our patients and their family members. The close relationships I develop with my patients and the continued efforts by my colleagues and me to find a cure inspire me to come to work every day with new hope and determination.

Biography: Dr. Furman is Director of the CLL Research Center at Weill Cornell Medicineand a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology. His area of focus is on the development of non-chemotherapeutic approaches to treating CLL, and has played an integral part in the development of ibrutinib and idelalisib.For More Videos, please see below:Lymphoma Cancer Treatment NY - Weill Cornell

Care Philosophy: As the Director of the Multiple Myeloma Center at New York Presbyterian Hospital-Cornell Medical Center, my duties will focus on providing outstanding clinical care and coordinating a world class clinical translational research program. Prestigious investigators have joined forces to create one of the leading centers for myeloma research. I have no doubt that this cooperative effort forms one of the best myeloma research groups on the World. My 25 years of experience as a myeloma physician has helped me to appreciate how important it is to treat patients in the context of a comprehensive and individualized program. New York Presbyterian Hospital has an outstanding Bone Marrow Transplant Service (a treatment modality often used for myeloma patients), performing more than 100 transplants per year. It has also been rated the best in the world in the fields of cardiology (heart), neurosurgery and nephrology (kidney). The Hospital for Special Surgery, also part of the New York Presbyterian-Weill Cornell system, has an outstanding group of orthopedic surgeons that support a new comprehensive bone disease program. In addition, as part of our continuing search for more effective therapeutic options, we offer multiple clinical trials utilizing promising new drugs and medical procedures for treating myeloma and related hematological disorders. The ultimate goal is to find the cure for multiple myeloma. The establishment of a free standing Multiple Myeloma Center at New York Presbyterian Hospital Weill Cornell Medical Center is an important step towards the accomplishment of this goal.

Care Philosophy: Dr. Shah and the Gastrointestinal Oncology group are committed to providing excellent and personalized care for you and your loved ones. We would welcome the opportunity to take part in your care, whether it involves primary management or for consultation in conjunction with your treating physicians. Ensuring you are receiving the best and most comprehensive treatment for your malignancy is our aim. Please feel free to contact us for an appointment, or have your physician contact us to discuss your care.

Biography: Christine A. Garcia, M.D., M.P.H. is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at New York-Presbyterian Hospital. Dr. Garcia cares for patients with lung cancer and patients with non-malignant (benign) hematological conditions. Additionally, she is the Director of Quality and Patient Safety and serves as the Chair of the Oncology Quality and Patient Safety Committee.Dr. Garcia received her undergraduate B.S. from University of Illinois at Urbana-Champaign. She received her M.P.H. from University of Illinois at Chicago. Prior to medical school, Dr. Garcia worked for the County of San Diego Health and Human Services and University of California San Diego. She received her medical degree from St. George's University with a Distinction in Research. She then received her internal medicine training at State University of New York at Stony Brook University Hospital, where she also served as a chief resident. Dr. Garcia completed her fellowship in hematology and oncology at the University of Pittsburgh Medical Center.Dr. Garcia's research is focused on quality improvement initiatives in cancer care. Additionally, she is the recipient of two American Society of Clinical Oncology (ASCO) Merit Awards in Palliative Care and Quality Care for her research related to quality improvement initiatives. She is a member of American Society of Clinical Oncology, American Society of Hematology (ASH), American College of Physicians (ACP) and Alpha Omega Alpha Medical Honor Society.

Care Philosophy: After developing an interest in fighting cancer in medical school, I was fortunate to work with and learn from leadersin the field of genitourinary oncology during internship, residency, and fellowship training. I feel fortunate to have joined the faculty at Weill Cornell to work with renowned mentors and colleagues in both medical oncology and urology. Together I am confident we will make progress towards increasing the cure rate and decreasing suffering from these diseases.

Biography: Fellowship: Hematology/Oncology at New York Presbyterian Hospital, 1997-2000Residency: New York Presbyterian Hospital, 1995-97Internship: The Beth Israel Hospital, Boston 1994-95Medical School: The Mount Sinai School of Medicine, New York, 1994Undergraduate: Yale University, 1990

Care Philosophy: Our lymphoma group practice provides specialized and multidisciplinary care in the setting of a leading medical institution for patients with all types of lymphomas. We strive to deliver the best possible standard of care, and take pride in our comprehensive clinical research program that provides access to state-of-the-art novel agents and combination treatments that continue to transform care for lymphoma patients, often years before they become widely available elsewhere. With a research background in tumor immunology and vascular medicine, my clinical research has been focused on developing new immunotherapy-based treatments that target the tumor microenvironment for a variety of lymphoma subtypes, including rare diseases such as mantle cell lymphoma and T-cell lymphoma. Another focus of mine is to develop low-intensity biologic-based treatments that minimize side effects and maximize quality-of-life. I believe in personalized, compassionate, and informed care that is tailored to each individual patient's needs.

Care Philosophy: Dr. Ritchie's research interests are in the treatment of older patients with anemia, cytopenias, myelodysplastic syndromes, myeloproliferative disorders and acute leukemia. She is interested in finding better therapies and supportive care strategies for older patients. Dr. Ritchie is the principal investigator on clincal trials investigating new diagnostic techniques, supportive care strategies and therapeutics aimed at the older patient. She collaborates with investigators in the Division of Geriatrics and Gerontology. She has been the author or co-author of many publications. She is interested in improving the medical care of older patients with hematologic malignancies.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Care Philosophy: My practice focuses on treating gastrointestinal malignancies, including colorectal, pancreatic, stomach, biliary, neuroendocrine, and liver cancers. I place great value on having strong physician-patient relationships and feel this is especially important in cancer care. I not only provide state-of-the art cancer treatment for my patients and their families, but comprehensive support through a compassionate and multidisciplinary approach. Through clinical research, I am able to offer my patients access to the latest therapies such as radiolabeled monoclonal antibodies, cancer "vaccines," immunotherapy, and other novel targeted agents. At Weill Cornell Medicine and New York-Presbyterian Hospital, we utilize a bench to bedside approach and are committed to bringing the most promising new treatments out of the lab and directly to patients often years before they are widely available elsewhere

Biography: Anna Pavlick, BSN, MSc, DO, MBA is a medical oncologist with over 20 years of experience treating patients with skin cancer, including melanoma, basal cell cancer,squamous cell cancer and Merkel cell carcinoma. She is also an expert in treating ocular melanoma, eyelid tumors and other rare solid tumor malignancies, including a research interest in neurofibromatosis-1 (NF1) malignancies. She is currently accepting new patients for both in-office visits and telehealth appointments.Dr. Pavlick was recruited to Weill Cornell Medicine as Professor of Medicine in the Division of Hematology & Medical Oncology. She is the founding Director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian. Dr. Pavlick's major research interests include investigating targeted therapies, combination therapies and immunotherapies. She also conducts outcomes research evaluating quality of life.Dr. Pavlick earned her medical degree from the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School; her Master of Science in Human Anatomy from Fairleigh Dickinson University; and her Bachelor of Science in Biology and Nursing degree from Fairfield University. She completed an internal medicine residency at UMDNJ and hematology and oncology fellowship training at Memorial Sloan Kettering Cancer Center. In addition to her undergraduate and medical training, Dr. Pavlick graduated from the Drexel School of Medicine Executive Leadership in Academic Medicine in 2012 and earned her Master of Business Administration (MBA) degree from Columbia University Business School in 2017.Dr. Pavlick has authored and co-authored over 100 publications and presented her research at international meetings. She serves on the several editorial boards, including The Journal of Drugs in Dermatology and The Journal of ImmunoTherapeutics of Cancer (Associate Editor). She is a member of leading oncology societies including American Society of Clinical Oncology (ASCO), American Academy of Clinical Research (AACR), the Society for Melanoma Research, Society for Immunotherapy and Translational Research in Cancer and the European Society of Medical Oncology (ESMO).

Biography: Dr. Cigler received her undergraduate degree from Harvard College, and her medical degree from Duke University School of Medicine. She also holds a Master's degree in Public Health from the Harvard School of Public Health. She completed her residency in Internal Medicine at New York Presbyterian Hospital Weill Cornell Medical Center, followed by a fellowship in Medical Oncology and Hematology at the Dana-Farber Harvard Cancer Center. Dr Cigler joined the Cornell faculty in August 2007 as a medical oncologist and clinical investigator at the Weill Cornell Breast Center.

Care Philosophy: For over a decade I have been taking care of people with lymphoma. At the end of every visit, I want people to know that I have taken the time to develop the plan that is the best for them. I am fortunate to work in a center where cancer care specialists can work along side experts in every field of medicine to care for the whole person. We are working every day to develop better treatments and integrate them into clinical practice. We have been involved in the development of virtually every drug approved for treatment of lymphoma over the past 15 years, including targeted therapies and immunotherapy. In our labs and our clinics we are developing the drugs of the future. We have made a lot of progress in the way lymphoma is diagnosed and treated, and I am determined to continue developing more effective, less toxic therapies.

Biography: Dr. John Mascarenhas, MD is an Oncology Specialist who practices in New York, NY. He is 52 years old. Dr. John Mascarenhas, MD is affiliated with Mount Sinai Hospital.

Care Philosophy: "I am a medical oncologist with an expertise in breast cancer medicine. My focus is the multidisciplinary care and treatment of patients, especially those who have tumors that are high risk. Because I am a passionate advocate of personalized medicine, my goal is to develop new successful treatments that exploit our knowledge of the cancer genome and the immuno cell network for immunotherapy, in order to improve the outcomes of breast cancer patients. To do this, I actively participate in team science and recognize the importance of establishing strong connections with other disciplines involved in the care of patients and who are in the laboratory, as our goals are the same- to cure breast cancer. I view my patients as individuals and welcome open and inclusive communication when discussing treatment strategies as it is paramount they feel comfortable with an established treatment pathway."

Care Philosophy: "Better people means better experiences. Our care team is committed to delivering results that change lives."

Biography: Dr. Daniel Labow, MD is a General Surgery Specialist who practices in New York, NY. He is 57 years old. Dr. Daniel Labow, MD is affiliated with Mount Sinai Morningside, Mount Sinai Queens and Mount Sinai Brooklyn.

Biography: Dr. Edward Wolin, MD is an Oncology Specialist who practices in New York, NY. He is 77 years old and has been practicing for 51 years. Dr. Edward Wolin, MD is affiliated with Mount Sinai Morningside.

Care Philosophy: Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

Care Philosophy: My main goal as an oncologist is to improve the quality and the duration of life of my patients and, all through their treatment, to develop an environment of compassion and mutual trust. Research in oncology is crucial for improving the prognosis of cancer patients and I have a strong passion for clinical and translational research. Each person is different and I am constantly striving to provide my patients the best personalized oncology care currently available for his or her specific condition. Additionally, I am committed to integrating innovative and more performant diagnostic and treatment methods within my practice.

Biography: Dr. Madhuri Devabhaktuni, MD is an Oncology Specialist who practices in New York, NY. She is 49 years old and has been practicing for 25 years. Dr. Madhuri Devabhaktuni, MD is affiliated with Mount Sinai Morningside, Mount Sinai Brooklyn and Mount Sinai Queens.

Biography: Dr. Khalid Dar, MD is an Oncology Specialist who practices in New York, NY. He is 75 years old and has been practicing for 51 years. Dr. Khalid Dar, MD is affiliated with Mount Sinai Morningside.

Biography: Mariam El-Ashmawy, MD PhD is a medical oncologist andtranslational scientist with specialization in the treatment of advanced skincancer and ocular melanoma. Her research investigates the complex geneticlandscape of cancer in order to develop new therapies. In the laboratory, her work has been dedicated to understanding the complex genomic landscape of cancer and developing novel targeted therapeutic strategies. Her ongoing projects include testing novel RAS pathway inhibitors in preclinical models of gastric and esophageal cancer as well as a first-in-human clinical trials for patients with NRAS mutant melanoma.

Biography: Dr. Fredric Harris, MD is an Oncology Specialist who practices in New York, NY. He is 79 years old. Dr. Fredric Harris, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Marshall Posner, MD is an Oncology Specialist who practices in New York, NY. He is 76 years old and has been practicing for 50 years. Dr. Marshall Posner, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Keren Osman, MD is an Oncology Specialist who practices in New York, NY. She is 55 years old and has been practicing for 29 years. Dr. Keren Osman, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Hanna Irie, MD is a Hematology Specialist who practices in New York, NY. She is 55 years old. Dr. Hanna Irie, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Krzysztof Misiukiewicz, MD is a Hematology Specialist who practices in New York, NY. He is 52 years old. Dr. Krzysztof Misiukiewicz, MD is affiliated with Mount Sinai Hospital.

Care Philosophy: As an oncologist, I believe providing the best state of the art treatment available for our patients. Our team of cancer specialists will ensure you will receive the best possible care.